**Section:** 8. Immunomodulators and antineoplastics  ➤  8.2. Antineoplastics and supportive medicines  ➤  8.2.1. Cytotoxic medicines

**Vincristine**

**Indication:** Malignant neoplasms of kidney, except renal pelvis  
**ICD11 code:** 2D40.Z

**INN:** Vincristine

**Medicine type:** Chemical agent

**List type:** Complementary

**Formulations:** Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate) ; 5 mg in vial (vincristine sulfate) ; 1 mg per mL in vial (vincristine sulfate) ; 2 mg per 2 mL in vial (vincristine sulfate)

**EML status history:**
- First added in 2011 (TRS 965)
- Changed in 2015 (TRS 994)
- Changed in 2021 (TRS 1035)

**Sex:** All

**Age:** Also recommended for children

**Therapeutic alternatives:** The recommendation is for this specific medicine

**Patent information:** Patents have expired in most jurisdictions

**Tags:** Cancer

**Wikipedia:** Vincristine

**DrugBank:** Vincristine

---

**Summary of evidence and Expert Committee recommendations**

The Expert Committee recommended the addition of new strength formulations of vincristine IV injection (1mg/mL and 2 mg/2mL) to the EML and EMLc.

**Expert Committee report**